Effects of FT011 in Systemic Sclerosis

Scleroderma, Systemic Clinical Trial

Official title:

A Phase II, Randomised, Double Blind, Placebo-controlled Study of the Pharmacokinetics, Pharmacodynamic Effects, and Safety, of Oral FT011 in Participants With Diffuse Systemic Sclerosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04647890
• Other study ID #: CER-FT011-SSc01
• Status: Completed
• Phase: Phase 2
• Start date: July 19, 2021
• Est. completion date: November 16, 2022

Study information

• Verified date: November 2023
• Source: Certa Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

FT011 is an anti-fibrotic drug that is being tested as a treatment for scleroderma. This study is being conducted to see what the body does to the drug (pharmacokinetics), and what the drug does to the body (pharmacodynamics).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: November 16, 2022
• Est. primary completion date: October 12, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Provide written informed consent prior to any study procedures and who agree to adhere to all protocol requirements.

2. Aged 18 to 75 years inclusive at the time of consent.

3. Have a classification of systemic sclerosis, as defined by American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) criteria with disease duration =10 years from first non-Raynaud phenomenon manifestation.

4. Have a diagnosis of diffuse cutaneous SSc defined as systemic sclerosis with skin thickening on the upper arms proximal to the elbows, on the upper legs proximal to the knees, or on the trunk.

5. Have skin thickening in a body area suitable for repeat biopsy.

6. Have a mRSS at Screening of =15 to =40.

7. FVC =50% of predicted at Screening.

8. If on azathioprine, mycophenolate mofetil, or hydroxychloroquine, have been on a stable dose for at least 2 months prior to baseline.

9. Women of childbearing potential (WOCPB) and males with partners of child-bearing potential must agree to use highly effective contraception (a failure rate of <1%), for the duration of the study and until three months after their last dose of IMP.

Exclusion Criteria:

1. Pregnant or breast-feeding, or plan to become pregnant during the study.

2. Have received any IMP within 30 days or 5 half-lives prior to randomisation (4 months if the previous drug was a new chemical entity), whichever is longer.

3. Have known or suspected contraindications to the IMP.

4. Have severe or unstable SSc or end-stage organ involvement as evidenced by:

1. On an organ transplantation list or has received an organ transplant including autologous stem cell transplant.

2. Renal crisis within 1 year prior to Baseline.

5. Interstitial lung disease or pulmonary hypertension requiring constant oxygen therapy. This excludes oxygen used to aid sleep or exercise.

6. Gastrointestinal dysmotility requiring total parenteral nutrition or requiring hospitalisation within the 6 months prior to Baseline.

7. Concomitant inflammatory myositis, rheumatoid arthritis, or systemic lupus erythematosus when definite classification criteria for those diseases are met (Bohan and Peter criteria for polymyositis and dermatomyositis)

8. SSc-like illnesses related to exposures or ingestions

9. The use of the following drugs within the specified periods:

1. Methotrexate in the 2 weeks prior to Day 1

2. Other anti-fibrotic agents including D-penicillamine or tyrosine kinase inhibitors (nilotinib, imatinib, dasatinib) in the month prior to Screening.

3. Biologic drugs such as tumour necrosing factor (TNF) inhibitors, tocilizumab, or Janus kinase (JAK) inhibitors, in the 3 months prior to Screening.

4. Rituximab in the 6 months prior to Screening.

5. Cyclophosphamide oral or IV in the 3 months prior to Screening.

6. Oral prednisolone >10 mg per day or IV steroids in the month prior to Screening.

10. Have any malignancy not considered cured (except basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix); a subject is considered cured if there has been no evidence of cancer recurrence for the 6 years prior to randomisation.

11. Have aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl transferase (GGT), lactate dehydrogenase (LDH), or bilirubin values above the upper limit of normal (ULN) at Screening or Baseline, or evidence of hepatic disease as determined by any one of the following: history of hepatic encephalopathy, history of oesophageal varices, or history of portacaval shunt.

12. Estimated glomerular filtration rate (eGFR) <60mL/min, urinary albumin/creatinine ratio >30mg/g.

13. Haemoglobin < 80 g/L, platelets < 90 x 109/L, or neutrophil count < 1.4 x 109/L

14. Other than SSc, have any other medical condition or significant co-morbidities, clinically relevant social or psychiatric conditions, or any finding during Screening, which in the investigator's opinion may put the subject at risk or interfere with the study objectives.

Related Conditions & MeSH terms

• Scleroderma, Diffuse
• Scleroderma, Localized
• Scleroderma, Systemic
• Sclerosis
• Sclerosis, Systemic

Intervention

Drug:
• FT011
Two x 100mg capsules once daily for 12 weeks
• FT011
Two x 200mg capsules once daily for 12 weeks
• Placebo
Two placebo capsules once daily for 12 weeks

Locations

Country	Name	City	State
Australia	Royal Adelaide Hospital	Adelaide	South Australia
Australia	St Vincent's Hospital Melbourne	Fitzroy	Victoria
Netherlands	Certa SSc trial site	Nijmegen
Poland	Certa SSc trial site	Bydgoszcz
Poland	Certa SSc trial site	Kraków
Poland	Certa SSc trial site	Malbork
Poland	Certa SSc trial site	Warsaw
Spain	Certa SSc trial site	Barcelona
Ukraine	Certa SSc trial site	Kyiv
Ukraine	Certa SSc trial site	Poltava

Sponsors (1)

Lead Sponsor	Collaborator
Certa Therapeutics

Countries where clinical trial is conducted

Australia,  Netherlands,  Poland,  Spain,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	FT011 Levels in Plasma	Measurement of maximum concentration (cmax) of FT011. First dose Cmax and last dose Cmax for each participant were averaged together to calculate a single mean Cmax for each treatment arm	Mean of cmax post first dose and cmax post last dose
Primary	FT011 Levels in Plasma	Measurement of time to cmax (tmax). First dose tmax and last dose tmax for each participant were averaged together to calculate a single mean tmax for each treatment arm	Mean of time to cmax post first dose and time to cmax post last dose
Primary	FT011 Levels in Plasma	Measurement of area under the concentration time curve (AUC). First dose AUC and last dose AUC for each participant were averaged together to calculate a single mean AUC for each active arm	Mean of AUC hours post first dose and AUC hours post last dose
Secondary	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) From Baseline to End of Study	TEAEs per arm during study treatment and follow up periods	Baseline to Week 16
Secondary	mRSS Change From Baseline	The mRSS is a validated physical evaluation of patient's skin thickness rated by clinical palpation using a 0-3 scale (0 = normal skin; 1 = mild thickness; 2 = moderate thickness; 3 = severe thickness with inability to pinch the skin into a fold) for each of 17 surface anatomic areas of the body: face, anterior chest, abdomen, and, with right and left sides of the body separately evaluated, the fingers, forearms, upper arms, thighs, lower legs, dorsum of hands and feet. Individual values are summed and defined as the total skin score. Total score is 0 to 51 with higher scores indicating worse symptomology	End of treatment (week 12)
Secondary	%FVC Change From Baseline	Percent predicted FVC is calculated using equations incorporating age, gender, and race. It is calculated as (FVC Observed / FVC predicted) x 100, where FVC predicted is calculated relative to a reference population	End of treatment (Week 12)
Secondary	Physician Global Assessment Change From Baseline	The physician's assessment of the patient's SSc status will be scored on a 100-mm horizontal VAS, ranging from 0 on the extreme left end of the scale indicating "no disease activity" (symptom free), and 100 on the extreme right end indicating "worst imaginable disease activity".	End of treatment (Week 12)
Secondary	Patient Global Assessment Change From Baseline	The Patient's Global Assessment represents the patient's overall assessment of current SSc status on a 100-mm horizontal VAS, ranging from 0 on the extreme left end of the scale indicating "no disease activity" (symptom free), and 100 on the extreme right end indicating "worst imaginable disease activity".	End of treatment (Week 12)
Secondary	Scleroderma HAQ-DI Change From Baseline	The HAQ-DI consists of 20 questions referring to eight component sets consisting of dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item is scored from 0 to 3. The eight scores of the eight sections are summed and divided by 8. The total score indicates the patient's self-assessed level of disability - higher scores indicate worse symptomology. A negative change from baseline indicates improvement. The Scleroderma HAQ (SHAQ) includes an additional five scleroderma-specific visual analogue scales (VAS), addressing overall disease activity, Raynaud's phenomenon, finger ulcers, breathing, and intestinal problems. A composite VAS score is not created nor are the individual VAS scores incorporated into the HAQ DI score.	End of treatment (Week 12)
Secondary	Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS) at Week 12	CRISS components include modified Rodnan skin score (mRSS), forced vital capacity percent predicted (%FVC), Physician Global Assessment, Patient Global Assessment, and Health Assessment Questionnaire Disability-Index (HAQ-DI). The exponential algorithm determines the predicted probability of improvement from baseline, incorporating change in these 5 components. The outcome is a continuous variable between 0.0 and 1.0 (0 - 100%). A higher score indicates greater improvement	Week 12
Secondary	Scleroderma Clinical Trial Consortium Damage Index (SCTC-DI) Change From Baseline	The SCTC-DI is a 23-item composite damage index to quantify organ damage in systemic sclerosis (0-55 scale; moderate damage >5, severe damage>12)	End of treatment (Week 12)
Secondary	5-D Itch Scale Change From Baseline	The 5-D itch scale is a 23-item validated instrument used to measure five domains of chronic itch: duration, degree, direction, disability, and distribution. Scores range from 5 to 25, with higher scores indicating a higher severity of chronic itch.	End of treatment (Week 12)